Trial Profile

A trial of MB-105 in relapsed and refractory CD5 positive T-cell lymphoma patients

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 29 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti-PSCA CAR-T cell therapy-City of Hope National Medical Center/Mustang Bio (Primary)
Indications T-cell lymphoma
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Oct 2024 New trial record
23 Oct 2024 According to a March Biosciences media release, on the basis of findings from this trial the company plans to begin a Phase 2 clinical trial in early 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com